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Fibroblasts are key effector cells in tissue remodeling. They remain persistently activated in fibrotic diseases, resulting in
progressive deposition of extracellular matrix. Although fibroblast activation may be initiated by external factors,
prolonged activation can induce an “autonomous,” self-maintaining profibrotic phenotype in fibroblasts. Accumulating
evidence suggests that epigenetic alterations play a central role in establishing this persistently activated pathologic
phenotype of fibroblasts. We demonstrated that in fibrotic skin of patients with systemic sclerosis (SSc), a prototypical
idiopathic fibrotic disease, TGF-β induced the expression of DNA methyltransferase 3A (DNMT3A) and DNMT1 in
fibroblasts in a SMAD-dependent manner to silence the expression of suppressor of cytokine signaling 3 (SOCS3) by
promoter hypermethylation. Downregulation of SOCS3 facilitated activation of STAT3 to promote fibroblast-to-
myofibroblast transition, collagen release, and fibrosis in vitro and in vivo. Reestablishment of the epigenetic control of
STAT3 signaling by genetic or pharmacological inactivation of DNMT3A reversed the activated phenotype of SSc
fibroblasts in tissue culture, inhibited TGF-β–dependent fibroblast activation, and ameliorated experimental fibrosis in
murine models. These findings identify a pathway of epigenetic imprinting of fibroblasts in fibrotic disease with
translational implications for the development of targeted therapies in fibrotic diseases.
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Introduction
Fibrotic tissue remodeling imposes a major burden on modern 
societies and has been estimated to contribute to up to 45% of 
deaths in the developed world and to cause socioeconomic costs 
on the order of tens of billions of dollars per year (1, 2). Fibrotic 
tissue remodeling may occur in response to trauma, infection/
inflammation, or tumors, but in many cases, no initiating triggers 
can be identified. Systemic sclerosis (SSc) is a prototypical exam-
ple of such an idiopathic fibrotic disease (3). Failure of the affected 
organs is common in SSc and results in high morbidity and mor-
tality, particularly because no targeted therapies are yet available 
for the treatment of fibrosis (3, 4). Aberrant activation of resident 
fibroblasts and their transition into myofibroblasts is the common 
denominator of fibrotic diseases (2–4). Overwhelming evidence 
highlights TGF-β as a core mediator of fibroblast activation (3–7). 
TGF-β signaling is chronically activated in SSc and other fibrotic 
diseases, and activated fibroblasts demonstrate a TGF-β–biased 
gene expression signature that persists in vitro (8–11). Moreover, 
TGF-β is sufficient to induce myofibroblast differentiation in vitro 
and tissue fibrosis in vivo (12).
Although myofibroblasts are only transiently observed during 
physiological wound healing, they persist in fibrotic diseases, 
resulting in persistent repair responses and progressive tissue 
fibrosis. More than 40 years ago, LeRoy and colleagues provid-
ed first evidence for an endogenous activation of SSc fibroblasts, 
demonstrating that SSc fibroblasts maintain an activated pheno-
type in vitro, even in the absence of other cell types or constitu-
ents of the profibrotic milieu in SSc (13). Endogenous activation 
of TGF-β in SSc fibroblasts in cell culture is critical to maintaining 
this persistently activated phenotype (14). This finding suggested 
that, although myofibroblast differentiation may initially be driv-
en by external factors, prolonged activation could render them 
autonomous and independent of external stimuli.
Changes in the epigenetic code are central for establishing 
and maintaining the activated phenotype of fibroblasts in fibrotic 
diseases (15–20). Among the different epigenetic modifications, 
DNA methylation remains most intensely studied. Methylation 
of DNA occurs on position 5 of the pyrimidine ring of cytosine 
residues within CpG dinucleotides and leads to transcription-
al silencing (21). A family of DNA methyltransferases (DNMT) 
comprising 3 members in mammals controls DNA methylation: 
DNMT1, which is predominantly a maintenance methyltransfer-
ase with a preference for hemimethylated sites, and DNMT3A 
and DNMT3B, which are thought to function mainly as de novo 
DNMTs (21–23). DNA methylation may drive fibrosis by silencing 
of antifibrotic genes (24–28), as evidenced by downregulation of 
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expression of SOCS proteins to provide a negative feedback loop 
(39). This endogenous feedback regulation is critical to prevent-
ing aberrant activation of JAK/STAT signaling. Loss-of-function 
mutations of SOCS proteins with consecutive activation of JAK/
STAT signaling have been observed in different hematologic and 
solid tumors (40–43). However, more commonly than by somat-
ic mutations, tumor cells escape the endogenous regulation of 
JAK/STAT signaling by epigenetic imprinting of SOCS genes (44). 
Hence, in various types of B cell neoplasias and carcinomas, the 
expression of SOCS1 or SOCS3 is silenced by DNA hypermethyl-
ation (43, 45–58).
In the present study, we tested the hypothesis that epigene-
tic silencing of SOCS expression may contribute to the aberrant 
activation of JAK2/STAT3 signaling by TGF-β in SSc and that rees-
tablishment of the endogenous, SOCS-dependent control of JAK/
STAT signaling may prevent aberrant fibroblast activation and 
ameliorate tissue fibrosis.
Results
The expression of SOCS3 is downregulated in SSc and in experimen-
tal skin fibrosis in a TGF-β–dependent manner. We first analyzed 
the expression of SOCS proteins in fibrotic skin of SSc patients. 
The mRNA and protein levels of SOCS3 were decreased in SSc 
skin as compared with that of healthy individuals of the same age 
and sex (Figure 1A). We also found reduced staining for SOCS3 
in fibroblasts in SSc skin by costaining for SOCS3 and the fibro-
blast marker prolyl-4-hydroxylase-β (P4Hβ, also known as PDI) 
(Figure 1B). The downregulation of SOCS3 persisted in cultured 
SSc fibroblasts with decreased mRNA and protein levels of 
SOCS3 as compared with fibroblasts from normal skin (Figure 
1C). The reduction of SOCS3 protein levels and of the number 
of SOCS3+ fibroblasts was more pronounced in diffuse-cutane-
ous SSc than in limited cutaneous SSc (Supplemental Figure 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI122462DS1). The expression of SOCS3 was 
also reduced in experimental fibrosis with decreased staining in 
vimentin-positive cells in the skin of mice challenged with bleo-
mycin as compared with nonfibrotic controls (Figure 1D). In con-
trast to SOCS3, we did not observe changes in SOCS1 expression 
in SSc or in experimental dermal fibrosis (data not shown), indi-
cating a SOCS3-specific deregulation.
Given the consistent downregulation of SOCS3 expression in 
human SSc skin, in cultured SSc fibroblasts, and in experimental 
fibrosis, we hypothesized that a core pathway of fibrosis, such as 
TGF-β, may regulate SOCS3 expression. Stimulation of cultured 
fibroblasts with recombinant TGF-β induced an early, transient 
upregulation of SOCS3 (Figure 1E). However, with prolonged fol-
low-up, the mRNA and protein levels of SOCS3 declined strongly 
to below baseline levels. The downregulation of SOCS3 was main-
tained and SOCS3 expression remained stably suppressed when 
fibroblasts were exposed to persistently increased levels of TGF-β 
as in fibrotic tissues (Figure 1E). In contrast, incubation of SSc fibro-
blasts with SD-208, a selective inhibitor of TGF-β receptor I kinase 
activity, increased SOCS3 expression to levels that were compara-
ble to those of normal fibroblasts (Supplemental Figure 2A). The 
regulatory effects of TGF-β on SOCS3 were confirmed in vivo. 
Activation of TGF-β signaling by overexpression of a constitutively 
the antifibrotic transcription factors FLI1 and KLF5 in SSc (29, 30). 
Those findings are of therapeutic interest, as epigenetic changes 
are reversible. DNMTs can be targeted by small molecule inhib-
itors, such as 5-azacitidine and 5-aza-2′-deoxycytidine (5-aza), 
which are already approved for clinical use in myelodysplastic 
syndrome and acute myeloid leukemia.
JAK/STAT signaling pathways are well established as crucial 
mediators of inflammation (31, 32). Small molecule inhibitors 
of JAKs are approved for clinical use in rheumatoid arthritis and 
await approval for other inflammatory diseases. In fibrotic diseas-
es, however, the role of JAK/STAT signaling is not restricted to the 
regulation of inflammation. We and others have demonstrated 
recently that JAK2/STAT3 signaling also transmits the profibrotic 
effects of TGF-β on fibroblasts and that targeted inhibition of JAK2 
or STAT3 ameliorates fibroblast activation and fibrosis (33–35). 
JAK2/STAT3 may thus not only modulate fibrotic tissue remod-
eling by regulating inflammatory responses, but also by directly 
controlling fibroblast activation. Two members of the suppressor 
of cytokine signaling (SOCS) proteins, SOCS1 and SOCS3, are 
crucial regulators of JAK/STAT signaling. The family of SOCS 
proteins consists of 8 members, SOCS1 to SOCS7 and cytokine-in-
duced SH2 containing protein (CIS), which share a central SH2 
domain and a SOCS box at the C-terminus. However, only SOCS1 
and SOCS3 possess an N-terminal kinase inhibitory region (KIR) 
domain, which enables them to block the transfer of phosphate 
from ATP to STAT proteins (36–38). SOCS1 and SOCS3 can thus 
act as noncompetitive inhibitors of JAKs. In addition, SOCS pro-
teins may also induce degradation of JAKs and of the associated 
cytokine receptors (39). Of note, SOCS proteins are transcriptional 
targets of STAT proteins: activation of STAT signaling induces the 
Figure 1. Decreased expression of SOCS3 in SSc and in experimental 
fibrosis. (A) Expression of SOCS3 in SSc and normal human skin. n = 9 
skin samples/group for qPCR with 2 technical replicates each; n = 4 skin 
samples/group for Western blot with 3 technical replicates each. (B) 
Representative fluorescence costaining for SOCS3 (green) with P4Hβ (red) 
and DAPI (blue) in skin sections of SSc patients and healthy controls and 
voronoi tessellation visualizing single-, double- and triple-positive cells. 
n = 8 skin samples/group. Scale bars: 250 μm. (C) Expression of SOCS3 in 
cultured human fibroblasts. n = 10 fibroblast lines from different donors for 
qPCR with 2 technical replicates each; n = 4 fibroblast lines from different 
donors for Western blot with 3 technical replicates each. (D) Socs3 expres-
sion in bleomycin-induced dermal fibrosis: mRNA levels and representative 
images of immunofluorescence staining together with voronoi tesselation 
visualizing single-, double-, and triple-positive cells for Socs3 and vimentin. 
Original magnification, ×600. n = 8 mice per group. Scale bars: 50 μm. (E) 
SOCS3 expression in normal human fibroblasts upon chronic stimulation 
with TGF-β. n = 5 fibroblast lines from different donors for qPCR with 2 
technical replicates each; n = 4 fibroblast lines from different donors for 
Western blot with 3 technical replicates each. (F) mRNA levels of Socs3 
in TBRIact- and bleomycin-induced fibrosis treated with the TBRI inhibitor 
SD-208. n = 5 mice/group with 2 technical replicates each. (G) Represen-
tative immunofluorescence stainings with voronoi tessellation visualizing 
single-, double-, and triple-positive cells for Socs3 and vimentin in the 
murine models of bleomycin- and TBRIact-induced dermal fibrosis with 
cotreatment with SD-208. n = 5 mice/group. Original magnification, ×600. 
Scale bars: 50 μm. Data are depicted as the median with interquartile 
range. Each dot represents an individual result. Mann-Whitney U test (A–D) 
or 1-way ANOVA with Tukey’s range test as post hoc analysis (E and F) was 
used for statistical analyses. 0.01 > **P ≥ 0.001; ***P < 0.001. 
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We also detected low levels of methylation at sites –1202 to –1053, 
–419 to –311, and –127 to +21, with trends toward slight increases 
in SSc fibroblasts (Figure 2C and Supplemental Figure 3). Consis-
tent with the lack of differences in expression of SOCS1, we did 
not observe differences in the methylation status of the promoter 
of SOCS1 in SSc fibroblasts (data not shown).
We next investigated whether epigenetic imprinting by pro-
moter hypermethylation also accounts for the repression of SOCS3 
expression upon prolonged stimulation with TGF-β. Indeed, incu-
bation with 5-aza prevented the downregulation of SOCS3 mRNA 
and protein in dermal fibroblasts from healthy donors upon pro-
longed exposure to TGF-β (Figure 2D). However, 5-aza did not 
further increase the levels of SOCS3 in SSc fibroblasts preincu-
bated for extended periods with SD-208 (Supplemental Figure 
2A), highlighting that the endogenous downregulation of SOCS3 
in SSc is dependent on the well-known hyperactive TGF-β signal-
ing in these cells (14). Moreover, repression of SOCS3 in the skin 
of TBRIact mice was reversed by the cotreatment with 5-aza (Fig-
ure 2E). Similar results were obtained in bleomycin-induced skin 
fibrosis (Figure 2F). Consistent with the findings obtained with 
5-aza, methylation-specific PCR and MeDIP assays demonstrat-
ed an upregulation of DNA methylation at the SOCS3 promoter at 
–784 to –654, the most highly methylated site in SSc fibroblasts, 
by TGF-β in normal fibroblasts, which was prevented by coincuba-
tion with 5-aza (Figure 2G).
To determine whether TGF-β promotes DNA methylation by 
regulation of DNMT expression, we monitored the expression lev-
els of all 3 DNMTs in fibroblasts stimulated with TGF-β over time. 
TGF-β upregulated the expression of DNMT1 and DNMT3A, but 
had no effect on the mRNA and protein levels of DNMT3B (Figure 
3A). Notably, the kinetics of the induction of DNMT1 and DNMT3A 
differed. First effects of TGF-β on DNMT3A expression occurred 
within 6 hours, with significant effects after 12 hours, while an 
induction of DNMT1 did not occur before 72 hours (Figure 3A). The 
differences in the kinetics suggest an indirect induction of DNMT1, 
whereas DNMT3A may be regulated directly by TGF-β. Indeed, the 
upregulation of DNMT3A mRNA by TGF-β did not require de novo 
protein synthesis, as analyzed by coincubation with cyclohexim-
ide (data not shown). Stimulation with TGF-β also induced DNMT 
activity in fibroblasts, with first effects within 4 hours (Figure 3B).
siRNA-mediated knockdown of SMAD3 and SMAD4 demon-
strated that TGF-β induces DNMT3A by canonical TGF-β signaling 
(Supplemental Figure 2, B and C). In contrast, targeted inhibition 
of noncanonical TGF-β downstream mediators such as JNK, p38, 
Ras, or Rac had no effect (data not shown). To further confirm 
the direct regulation of DNMT3A expression by TGF-β–induced 
SMAD3 signaling, we analyzed the DNMT3A promoter for poten-
tial SMAD3-binding sites and performed ChIP assay. In silico anal-
yses of the DNMT3A promoter revealed 4 SMAD-binding elements 
(SBE). ChIP assays demonstrated that TGF-β induced SMAD3 
binding to the DNMT3A promoter at –3423 bp (Supplemental Fig-
ure 2D). Thus, TGF-β regulates DNA methylation in fibroblasts by 
SMAD3-dependent upregulation of DNMT3A expression.
The different kinetics of DNMT1 and DNMT3A induction by 
TGF-β may also reflect the functional differences of both DNMTs, 
with DNMT3 acting predominantly as a de novo DNMT and 
DNMT1 rather maintaining established DNA methylation (21). 
active TGF-β receptor type I (TBRIact) decreased the expression of 
Socs3 in murine skin (Figure 1, F and G). Moreover, the downreg-
ulation of Socs3 in bleomycin- and TBRIact-induced fibrosis was 
blocked by selective inhibition of TGF-β signaling with SD-208 
(Figure 1, F and G), confirming that TGF-β is both sufficient and 
required to downregulate SOCS3 expression in skin fibrosis.
TGF-β inhibits SOCS3 expression by hypermethylation of the 
SOCS3 promoter. The findings of a persistent downregulation of 
SOCS3 expression in cultured SSc fibroblasts and the repression 
of SOCS3 upon stimulation with TGF-β suggested that epigenetic 
mechanisms might account for the reduced expression of SOCS3. 
In cancer cells, the transcription of SOCS3 has been shown to be 
regulated by DNA methylation (54, 59). To evaluate whether DNA 
methylation is implicated in the downregulation of SOCS3 expres-
sion in SSc, we first inhibited the activity of DNMT by 5-aza. In 
SSc fibroblasts, incubation with 5-aza increased the mRNA and 
protein levels of SOCS3 in a time-dependent manner (Figure 2A). 
In contrast, 5-aza had no significant effects on the steady-state 
expression of SOCS3 in fibroblasts derived from healthy individ-
uals (“normal” fibroblasts) (Figure 2B). To directly demonstrate 
hypermethylation of the promoter region of the SOCS3 gene in 
SSc fibroblasts, we performed methylation-specific PCR. The 
ratio of methylated to unmethylated DNA was higher in fibroblasts 
from SSc skin compared with fibroblasts isolated from the skin of 
healthy individuals (Figure 2C). Methylated DNA immunoprecip-
itation (MeDIP) analysis of 14 sites throughout the CpG island in 
the promoter of the SOCS3 gene demonstrated that hypermeth-
ylation occurs in particular at –1402 to –1313, –981 to –545, –784 
to –654, –661 to –545, –353 to –223, and +75 to +217 with 40- to 
100-fold increases in SSc fibroblasts as compared with fibroblasts 
from healthy individuals. These sites were consistently hyper-
methylated in all lines of fibroblasts derived from patients with 
diffuse-cutaneous SSc (Figure 2C and Supplemental Figure 3). 
Figure 2. Regulation of SOCS3 expression by DNA methylation. (A) SOCS3 
expression in SSc fibroblasts incubated with 5-aza. n = 6 fibroblast lines 
from different donors for qPCR with 2 technical replicates each; n = 5 
fibroblast lines from different donors for Western blot with 3 technical rep-
licates each. (B) Effects of 5-aza on SOCS3 expression in SSc and normal 
fibroblasts. n = 5 fibroblast lines from different donors for qPCR with 2 
technical replicates each; n = 5 fibroblast lines from different donors for 
Western blot with 3 technical replicates each. (C) Promoter methylation of 
SOCS3 by methylation-specific PCR (MSP) (U, unmethylated; M, methyl-
ated PCR) and MeDIP assay in SSc and normal fibroblasts incubated with 
5-aza. n = 7 fibroblast lines from different donors for MSP with 3 technical 
replicates each; n = 5 fibroblast lines from different donors for MeDIP with 
4 technical replicates each. (D) SOCS3 expression in normal fibroblasts 
stimulated with TGF-β and incubated with 5-aza. n = 5 fibroblast lines 
from different donors for both qPCR and Western blot with 2 technical 
replicates each. (E and F) Socs3 expression in (E) TBRIact- and (F) bleo-
mycin-induced fibrosis treated with 5-aza. n = 5 mice/group for qPCR 
with 2 technical replicates each; n = 3 mice/group for Western blot with 3 
technical replicates each. (G) Promoter methylation of SOCS3 induced by 
TGF-β in normal human fibroblasts as analyzed by MSP and MeDIP assay. 
n = 10 fibroblast lines from different donors for MSP with 2 technical rep-
licates each; n = 5 fibroblast lines from different donors for MeDIP with 4 
technical replicates each. Data are depicted as the median with interquar-
tile range. Each dot represents an individual result. One-way ANOVA with 
Tukey’s range test as post hoc analysis was used for statistical analyses. 
0.01 > **P ≥ 0.001; ***P < 0.001.
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Consistent with this interpretation, individual knockdown of 
DNMT3A, but also of DNMT1, was each sufficient to completely 
prevent the downregulation of SOCS3 upon prolonged incubation 
with TGF-β in normal fibroblasts and to reactivate the baseline 
expression of SOCS3 in SSc fibroblasts (Figure 3, C and D).
In line with increased TGF-β signaling in fibrotic tissues and 
the endogenous activation of TGF-β signaling in cultured SSc fibro-
blasts, we observed increased mRNA and protein levels of DNMT1 
and DNMT3A, but not of DNMT3B, in SSc skin and in SSc fibroblasts 
compared with matched healthy skin and normal dermal fibroblasts, 
respectively (Figure 3, E and F). Moreover, incubation with SD-208 
decreased DNMT1 and DNMT3A expression in SSc fibroblasts to 
levels comparable to those of normal fibroblasts, suggesting that the 
increased expression of DNMT1 and DNMT3A depends on auto-
crine TGF-β signaling in SSc fibroblasts (Supplemental Figure 2E). 
Together, these data demonstrate that TGF-β induces DNMT3A and 
DNMT1 in a SMAD-dependent manner to silence the expression of 
SOCS3 by promoter hypermethylation in SSc.
SOCS3 limits TGF-β–dependent fibroblast activation. To investi-
gate the functional role of SOCS3 in fibroblast activation in SSc, we 
first targeted the expression of SOCS3 in fibroblasts. siRNA-me-
diated knockdown of SOCS3 in dermal fibroblasts from healthy 
volunteers increased mRNA levels of COL1A1 and COL1A2, stim-
ulated the release of collagen protein, and promoted the expres-
sion of α-smooth muscle actin (α-SMA) and the formation of stress 
fibers to levels almost comparable to those of SSc fibroblasts (Fig-
ure 4A and Supplemental Figure 4B). In contrast to the effects on 
normal fibroblasts, knockdown of SOCS3 had no further effects 
on collagen release or the expression of myofibroblast markers in 
SSc fibroblasts, a finding that is in line with the promoter methyla-
tion-induced silencing of SOCS3 in SSc fibroblasts (Figure 4C and 
Supplemental Figure 4D).
Coincubation with 5-aza to prevent the downregulation of 
SOCS3 reduced the stimulatory effects of TGF-β on normal fibro-
blasts and reduced the upregulation of COL1A1 and COL1A2 
mRNA, collagen protein, α-SMA, and fibers (Figure 4A and Sup-
plemental Figure 4B), but had no significant effects on the basal 
expression levels in normal fibroblasts. Moreover, incubation with 
5-aza also reversed the activated phenotype of established myo-
fibroblasts when applied 72 hours after first exposure to TGF-β 
(Supplemental Figure 5). Incubation with 5-aza also inhibited the 
aberrant activation of SSc fibroblasts and reduced the release of 
collagen as well as the expression of myofibroblast markers (Fig-
ure 4C and Supplemental Figure 4D). Selective inactivation of 
DNMT3A or DNMT1 by siRNA-mediated knockdown also inhib-
ited the TGF-β–induced activation of fibroblasts isolated from 
healthy donors and decreased the basal activation of SSc fibro-
blasts (Figure 4, B and D, and Supplemental Figure 4, C and D).
To exclude that the increased sensitivity of SSc fibroblasts to 
the antifibrotic effects of 5-aza is based on enhanced proliferation 
of these cells, all experiments were performed with confluent and 
thus contact-inhibited, nonproliferating cells. Moreover, coincu-
bation with cell cycle inhibitors did not ameliorate the differenc-
es in responsiveness to 5-aza between SSc fibroblasts and normal 
fibroblasts (data not shown).
In contrast, forced overexpression of SOCS3 inhibited TGF-β–
induced fibroblast activation in normal fibroblasts with reduced 
induction of COL1A1 and COL1A2 mRNA as well as the release of 
collagen (Figure 5, A and B). Overexpression of SOCS3 also amelio-
rated the activated phenotype of SSc fibroblasts (Figure 5, C and D).
Inhibition of epigenetic silencing of Socs3 ameliorates experimen-
tal fibrosis. To investigate the role of Socs3 in the pathogenesis 
of experimental fibrosis, we evaluated the outcome of mice with 
fibroblast-specific deletion of Socs3 (Socs3fl/fl Col6Cre) in bleomy-
cin- and TBRIact-induced skin fibrosis. Socs3fl/fl and Col6Cre mice 
presented with normal skin architecture and responses to profi-
brotic stimuli comparable to those of WT mice (data not shown). 
Socs3fl/fl Col6Cre double-transgenic mice also showed a normal 
skin architecture under homeostatic conditions. However, Socs3fl/
fl Col6Cre mice demonstrated enhanced responses to profibrotic 
stimuli (Figure 6, A–D, and Supplemental Figure 6A). In the mouse 
model of bleomycin-induced skin fibrosis, dermal thickening, 
myofibroblast accumulation, and hydroxyproline content were 
more pronounced in Socs3fl/fl Col6Cre mice compared with Socs3fl/
fl control mice (Figure 6, A and B). Consistent with the regulatory 
effects of SOCS3 on TGF-β–induced fibroblast activation, Socs3fl/fl 
Col6Cre mice were also more sensitive to TBRIact-induced fibrosis 
compared with Socs3fl/fl mice (Figure 6, C and D).
To further highlight the role of DNA methylation–induced 
silencing of SOCS3 in the pathogenesis of skin fibrosis, we treated 
Socs3fl/fl Col6Cre mice and control littermates with 5-aza. Treat-
ment with 5-aza ameliorated bleomycin- and TBRIact-induced skin 
fibrosis in Socs3fl/fl control mice, with reduced dermal thickening, 
decreased myofibroblast counts, and lower hydroxyproline content 
(Figure 6, A–D). In control mice, treatment with 5-aza not only pre-
vented fibrosis in control littermates, but also induced regression of 
preestablished bleomycin-induced fibrosis (Supplemental Figure 
7). In contrast with what occurred in control mice, treatment with 
5-aza did not demonstrate pronounced antifibrotic effects in Socs3fl/fl 
Col6Cre mice (Figure 6, A–D), providing further evidence for the 
pathophysiologic relevance of the epigenetic deregulation of SOCS3 
in fibrotic conditions. Treatment with 5-aza was well tolerated with-
out evidence of weight loss or other signs of toxicity, such as chang-
Figure 3. Dysregulated expression of DNMT3A. (A) mRNA and protein lev-
els of DNMT1, DNMT3A, and DNMT3B upon chronic stimulation with TGF-β 
in normal dermal fibroblasts. n = 5 fibroblast lines from different donors 
with 2 technical replicates each for qPCR; n = 3 fibroblast lines from differ-
ent donors with 3 technical replicates each for Western blot. (B) Activity 
of DNMTs upon chronic stimulation with TGF-β. n = 4 fibroblast lines from 
different donors with 2 technical replicates each. (C) mRNA and protein 
levels of SOCS3 and DNMT3A upon knockdown of DNMT3A in TGF-β–stim-
ulated normal fibroblasts. n = 12 fibroblast lines from different donors for 
qPCR with 2 technical replicates each; n = 3 fibroblast lines from different 
donors for Western blot with 3 technical replicates each. (D) Expression 
of SOCS3 upon knockdown of DNMT1 or DNMT3A in SSc fibroblasts. n = 4 
fibroblast lines from different donors with 2 technical replicates each. (E 
and F) mRNA and protein levels of DNMT1, DNMT3A, and DNMT3B in (E) 
human skin and (F) human cultured fibroblasts. n = 6 fibroblast lines or 
skin samples from different donors for qPCR with 2 technical replicates 
each; n = 4 fibroblast lines or skin samples from different donors for West-
ern blot with 3 technical replicates each. Data are depicted as the median 
with interquartile range. Each dot represents an individual result. One-way 
ANOVA with Tukey’s range test as post hoc analysis (A–D) or Mann-Whit-
ney U test (E and F) was used for statistical analyses. 0.05 > *P ≥ 0.01; 0.01 
> **P ≥ 0.001; ***P < 0.001.
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dermal thickening, myofibroblast counts, 
and collagen deposition upon challenge 
with bleomycin (Figure 7, A and B, and Sup-
plemental Figure 6B) or TBRIact-AAV (Fig-
ure 7, C and D) compared with Dnmt3afl/
fl mice. In agreement with a Dnmt3a-in-
duced downregulation of Socs3, additional 
treatment of Dnmt3afl/fl Col6Cre mice with 
5-aza had no additive antifibrotic effects.
We also investigated whether individ-
ual knockdown of Dnmt1 or of Dnmt3a 
may induce regression of preestablished 
experimental skin fibrosis. Indeed, knock-
down of Dnmt1 or Dnmt3a not only pre-
vented progression of bleomycin-induced 
skin fibrosis, but reduced dermal thick-
ness, myofibroblast counts, and hydroxy-
proline content to below pretreatment lev-
els despite ongoing bleomycin challenge 
(Supplemental Figure 8).
SOCS3 inhibits JAK2/STAT3 signal-
ing to regulate TGF-β–dependent fibroblast 
activation. SOCS3 can bind to JAK1, JAK2, 
and TYK2 to inhibit their kinase activity, 
preventing subsequent activation of STAT 
and transcription of STAT-dependent tar-
get genes (37, 38). We and others previously 
demonstrated that stimulation with TGF-β activates JAK2/STAT3 
signaling in fibroblasts, characterized JAK2 and STAT3 as import-
ant intracellular mediators of TGF-β signaling, and demonstrated 
enhanced activation of JAK2/STAT3 signaling with accumulation of 
phosphorylated JAK2 (pJAK2) and phosphorylated STAT3 (pSTAT3) 
es in the texture of the fur, reduced activity, other abnormal behav-
ior, or altered consistency of the stool in mice treated with 5-aza.
In contrast to the knockout of Socs3 in fibroblasts, mice with 
fibroblast-specific knockout of Dnmt3a (Dnmt3afl/fl Col6Cre) were 
protected from experimental fibrosis and demonstrated reduced 
Figure 4. Knockdown of SOCS3 promotes 
fibroblast activation, while inactivation of 
DNMTs prevents it. (A) mRNA levels of COL1A1 
and COL1A2 and collagen protein levels upon 
knockdown of SOCS3 in fibroblasts from healthy 
individuals stimulated with TGF-β and incubated 
with 5-aza. n = 6 fibroblast lines from differ-
ent donors with 2 technical replicates each for 
all conditions. (B) mRNA levels of COL1A1 and 
COL1A2 and collagen protein levels upon knock-
down of DNMT3A in normal dermal fibroblasts 
stimulated with TGF-β. n = 6 fibroblast lines from 
different donors with 2 technical replicates each. 
(C) mRNA levels of COL1A1 and COL1A2 and colla-
gen content in cell culture media upon knock-
down of SOCS3 in fibroblasts from SSc patients. 
n = 8 fibroblast lines from different donors with 
2 technical replicates each for all conditions. (D) 
mRNA levels of COL1A1 and COL1A2 and relative 
collagen content in cell culture media after 
knockdown of DNMT1 or DNMT3A in fibroblasts 
from SSc patients. n = 8 fibroblast lines from dif-
ferent donors with 2 technical replicates each for 
all conditions. Data are depicted as the median 
with interquartile range. Each dot represents an 
individual result. One-way ANOVA with Tukey’s 
range test as post hoc analysis was used for 
statistical analyses. ***P < 0.001.
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blasts with 5-aza restored the negative feedback regulation by 
SOCS3 with increased binding of SOCS3 to JAK2 and decreased 
interaction of JAK2 with STAT3 (Figure 8A). Consistently, coin-
cubation with 5-aza inhibited the stimulatory effects of TGF-β on 
STAT3-regulated transcription in reporter assays (Figure 8B). The 
inhibitory effects of 5-aza on STAT3-dependent transcription were 
absent in SOCS3 knockdown fibroblasts. In contrast, knockdown 
of DNMT3A significantly decreased responsiveness to TGF-β and 
reduced STAT3 reporter activity (Figure 8B). Forced overexpres-
sion of SOCS3 inhibited STAT3-dependent transcriptional activity 
in these assays, and the effect of forced overexpression of SOCS3 
was not sensitive to 5-aza (data not shown).
To further demonstrate that the activated phenotype of SOCS3 
knockdown fibroblasts is caused by hyperactivation of JAK2/STAT3 
signaling, we overexpressed a mutant version of JAK2 with point muta-
tions in the GQM-binding motif that is required for binding of SOCS3 
(JAK2-G1071V;M1073A) (Supplemental Figure 10) (36). Incubation 
with 5-aza upon forced overexpression of WT JAK2 (JAK2-WT) dimin-
ished the TGF-β–induced increases in pSTAT3 levels, collagen and 
α-SMA expression, and stress fiber formation (Figure 8, C–E). How-
in SSc (33–35, 60). We thus tested the hypothesis that SOCS3 may 
regulate fibroblast activation by inhibiting TGF-β–induced JAK2/
STAT3 signaling. Indeed, when we knocked down JAK2 in addition 
to SOCS3 in normal fibroblasts, we were able to completely rescue 
the activated phenotype of SOCS3 knockdown fibroblasts (Supple-
mental Figure 9). The mRNA levels of COL1A1 and of COL1A2 and 
the release of collagen protein were reduced in fibroblasts with com-
bined knockdown of JAK2 and SOCS3 compared with fibroblasts 
with individual knockdown of SOCS3 and were similar to those of 
fibroblasts with individual knockdown of JAK2 (Supplemental Fig-
ure 9A). In addition, coknockdown of JAK2 in addition to SOCS3 
reduced the activation of fibroblasts with decreases in α-SMA 
expression and stress fiber formation (Supplemental Figure 9B).
Given the regulation of SOCS3 by promoter hypermethylation, 
inhibition of the epigenetic silencing of SOCS3 should ameliorate 
TGF-β–induced JAK2/STAT3 signaling. Indeed, coincubation of 
normal dermal fibroblasts with 5-aza prevented the accumulation 
of pSTAT3 upon prolonged stimulation with TGF-β, whereas knock-
down of SOCS3 promoted it (Supplemental Figure 9C). Co-IP fur-
ther demonstrated that coincubation of TGF-β–stimulated fibro-
Figure 5. Overexpression of SOCS3 inhibits collagen release. (A and B) Overexpression of SOCS3 in dermal fibroblasts from healthy individuals. (A) 
mRNA and protein levels of SOCS3 upon forced overexpression of SOCS3 in fibroblasts from healthy individuals. n = 6 fibroblast lines from different 
donors with 2 technical replicates each for qPCR; n = 3 fibroblast lines from different donors with 2 technical replicates each for Western blot. (B) mRNA 
levels of COL1A1 and COL1A2 and relative collagen protein in cell culture supernatant upon overexpression of SOCS3 and stimulation with TGF-β. n = 6 
fibroblast lines from different donors with 2 technical replicates each. (C and D) Overexpression of SOCS3 in SSc fibroblasts. (C) mRNA and protein levels 
of SOCS3 upon forced overexpression of SOCS3 in fibroblasts from SSc patients. n = 6 fibroblast lines from different donors with 2 technical replicates 
each for qPCR; n = 4 fibroblast lines from different donors with 3 technical replicates each for Western blot. (D) COL1A1 and COL1A2 mRNA and relative 
collagen protein in cell culture supernatant. n = 5 fibroblast lines from different donors with 2 technical replicates each. Data are depicted as the median 
with interquartile range. Each dot represents an individual result. One-way ANOVA with Tukey’s range test as post hoc analysis was used for statistical 
analyses. 0.05 > *P ≥ 0.01; 0.01 > **P ≥ 0.001; ***P < 0.001.
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Discussion
In the present study, we demonstrate that the expression of 
SOCS3 is reduced in fibroblasts of the fibrotic skin of SSc patients, 
a phenotype that persists even in isolated fibroblasts after long-
term in vitro culture. The expression of Socs3 is also decreased 
in murine models of skin fibrosis. We show on multiple experi-
mental levels that canonical TGF-β signaling plays an important 
role for the downregulation of SOCS3: (a) incubation with recom-
binant TGF-β decreased the mRNA and protein levels of SOCS3 
in cultured fibroblasts; (b) selective activation of TGF-β signaling 
by overexpression of TBRIact reduced the expression of Socs3 in 
murine skin; and (c) treatment with SD-208, a selective inhibi-
tor of TGF-β receptor type I (61), prevented the downregulation 
of Socs3 in experimental fibrosis. Each of these findings demon-
strates that TGF-β signaling is required to downregulate SOCS3 
in fibrosis. However, in addition, other factors relevant to the 
pathogenesis of fibrosis and SSc, such as hypoxia, may regulate 
the expression of SOCS3 and hence may contribute to the SOCS3 
decrease in patients with SSc (50, 62).
Mechanistically, TGF-β reduces the expression of SOCS3 by 
induction of DNMT3A, which silences SOCS3 expression by DNA 
methylation. We demonstrate by methylation-specific PCR and 
MeDIP assays that the promoter of SOCS3 is hypermethylated in 
ever, the antifibrotic effects of 5-aza were blunted in JAK2-G1071V;-
M1073A fibroblasts. In contrast to what occurred with controls, 5-aza 
did not change the levels of pSTAT3, collagen, and the expression of 
myofibroblast markers in TGF-β–stimulated JAK2-G1071V;M1073A 
fibroblasts (Figure 8, C–E). Together, these data demonstrate that the 
antifibrotic effects of 5-aza are mainly mediated by SOCS3-regulated 
inhibition of JAK2/STAT3 signaling.
To confirm these findings in cultured fibroblasts in the con-
text of fibrosis, we analyzed the effects of knockdown of Socs3 and 
Dnmt3a and of treatment with 5-aza on the activation of Jak2/Stat3 
signaling in experimental fibrosis. Immunofluorescence staining of 
pJak2 and pStat3 in the dermis of bleomycin- and TBRIact-induced 
fibrosis models showed that inhibition of DNA methylation by 5-aza 
effectively reduced Jak2/Stat3 signaling in experimental fibrosis 
(Supplemental Figures 11–14). However, such inhibitory effects of 
5-aza on Jak2/Stat3 activation were not observed in fibroblast-spe-
cific Socs3 mutants (Socs3fl/fl Col6Cre mice), indicating that Socs3 
essentially regulates Jak2/Stat3 signaling. (Supplemental Figures 11 
and 12). Conversely, when investigating fibroblast-specific Dnmt3a 
mutants (Dnmt3afl/fl Col6Cre mice), which are associated with 
high-level Socs3 expression, bleomycin and TBRIact did not achieve 
Jak2 and Stat3 activation (Supplemental Figures 13 and 14). Also, 
5-aza had no further effects on Jak2 and Stat3 activation.
Figure 6. Fibroblast-specific knockout of Socs3 exacerbates experimental fibrosis. (A and B) Bleomycin-induced dermal fibrosis. (A) Representative tri-
chrome-stained skin sections. Original magnification, ×100. Scale bars: 250 μm. (B) Quantitation of dermal thickness, myofibroblast counts, and hydroxy-
proline content. n ≥ 7 mice per group. (C and D) TBRIact-induced dermal fibrosis. (C) Representative trichrome-stained skin sections. Original magnification, 
×100. Scale bars: 250 μm. (D) Quantitation of dermal thickness, myofibroblast counts, and hydroxyproline content. n = 5 mice per group. Data are depicted 
as the median with interquartile range. Each dot represents an individual result. One-way ANOVA with Tukey’s range test as post hoc analysis was used 
for statistical analyses. 0.05 > *P ≥ 0.01; 0.01 > **P ≥ 0.001; ***P < 0.001.
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DNA hypermethylation in SSc and that their silencing is directly 
implicated into different aspects of the pathogenesis of SSc (29, 
30, 64). Our study demonstrates, using the example of SOCS3, 
that the aberrant activation of DNMTs in SSc can also promote 
activation of profibrotic transcriptional programs. Inactivation of 
SOCS3 lowers the threshold for STAT3 activation and results in 
prolonged activation of STAT3, which may directly contribute to 
the autonomous activation of SSc fibroblasts. Silencing of SOCS3 
amplified the responsiveness of fibroblasts to TGF-β, and fibro-
blast-specific deletion of Socs3 in vivo worsened skin fibrosis. In 
contrast, forced expression of SOCS3, knockout of DNMT3A, or 
treatment with 5-aza inhibited TGF-β–induced myofibroblast dif-
ferentiation, collagen production, and skin fibrosis. Induction of 
DNMT3A with subsequent silencing of SOCS3 thus directly con-
tributes to the profibrotic effects of TGF-β.
These findings may have therapeutic implications. They high-
light a central role of STAT3 in the pathogenesis of SSc and demon-
strate that activation of STAT3 signaling is sufficient to promote 
fibroblast activation and contributes to the activated phenotype of 
SSc fibroblasts. Reestablishment of the endogenous feedback reg-
ulation of STAT signaling either by forced reexpression of SOCS3 
or by inhibition of DNA methylation by targeting DNMT3A reduc-
es the endogenous activation of SSc fibroblasts, limits the profi-
SSc fibroblasts compared with fibroblasts from healthy individu-
als. Stimulation of normal fibroblasts with recombinant TGF-β 
not only leads to transformation into an SSc-like fibroblast pheno-
type, but also upregulates methylation of the SOCS3 promoter to 
levels comparable to those observed in SSc fibroblasts. The down-
regulation of SOCS3 in SSc fibroblasts is thus consistent with the 
persistent activation of TGF-β signaling in these cells even after 
several passages in vitro (4). The stimulatory effects of TGF-β on 
SOCS3 promoter methylation are mediated by a SMAD-depen-
dent induction of DNMT3A. Prolonged incubation with TGF-β 
also induced the expression of DNMT1. However, the kinetic pro-
files of DNMT3A and DNMT1 upregulation suggest that DNMT3A 
is induced directly and operates as de novo DNMT at the SOCS3 
promoter, whereas DNMT1 is induced indirectly and rather serves 
to maintain the preexisting DNA methylation marks (21). Accord-
ing to this model, the activity of both DNMTs would be required 
to chronically sustain promoter hypermethylation of SOCS3 and 
inactivation of either DNMT1 or DNMT3A would prevent chronic 
silencing of SOCS3 and other target genes (24, 63). Consistent-
ly, we found that, in addition to the pronounced upregulation of 
DNMT3A, the expression of DNMT1 was also increased in SSc.
Previous elegant studies demonstrated that the protective 
antifibrotic transcription factors FLI1 and KLF5 are silenced by 
Figure 7. Fibroblast-specific knockout of Dnmt3a ameliorates experimental fibrosis. (A and B) Bleomycin-induced dermal fibrosis. (A) Representative tri-
chrome-stained skin sections. Original magnification, ×100. Scale bars: 250 μm. (B) Quantitation of dermal thickness, myofibroblast counts, and hydroxy-
proline content. n = 7 mice per group. (C and D) TBRIact-induced dermal fibrosis. (C) Representative trichrome-stained skin sections. Original magnification, 
×100. Scale bars: 250 μm. (D) Quantitation of dermal thickness, myofibroblast counts, and hydroxyproline content. n = 5 mice per group. Data are depicted 
as the median with interquartile range. Each dot represents an individual result. One-way ANOVA with Tukey’s range test as post hoc analysis was used 
for statistical analyses. 0.01 > **P ≥ 0.001; ***P < 0.001.
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of manifestations of SSc. However, further studies in additional 
preclinical models that better resemble vascular and inflammatory 
manifestations of SSc are warranted to confirm this hypothesis.
In summary, we demonstrate that chronic activation of TGF-β 
signaling perturbs the epigenetic control of STAT signaling by 
DNMT3A-induced silencing of SOCS3 expression (Figure 9). 
Reestablishment of the endogenous regulation of STAT signaling, 
either by forced expression of SOCS3 or by inhibition of DNMTs, 
prevents aberrant STAT3 signaling, inhibits TGF-β–induced fibro-
blast activation and collagen release, and ameliorates experimen-
tal fibrosis. Restoration of the epigenetic control of STAT3 signal-
ing might thus be a novel approach for the treatment of fibrotic 
diseases such as SSc.
Methods
Patients and fibroblast cultures. Skin biopsies were obtained from the 
forearms of 38 SSc patients and 42 age- and sex-matched healthy vol-
unteers. All patients fulfilled the American College of Rheumatology 
(ACR)/European League Against Rheumatism (EULAR) criteria for 
SSc (68). Twenty-two patients had diffuse cutaneous SSc and 16 had 
limited cutaneous SSc. The median age of SSc patients was 46 years 
(range: 19–70 years), and their median disease duration was 5 years 
(range: 0.5–12 years). All patients were positive for anti-nuclear Abs; 
14 patients were positive for anti–topoisomerase-1 Abs, and 12 were 
positive for anti-centromere Abs, 2 for anti-RNAIII polymerase Abs. 
Patients did not receive any disease-modifying anti-rheumatic drug 
treatment at the time of biopsy.
Cell culture. Fibroblasts were prepared by outgrowth of skin biop-
sies and cultured as described (69–71). Dermal fibroblasts were stim-
ulated with recombinant TGF-β (10 ng/mL; Peprotech) for different 
time intervals up to 120 hours. For inhibition of DNMTs, cells were 
incubated with 5-aza (Sigma-Aldrich) in concentrations of 1 μM and 
10 μM for different time intervals. In a subset of experiments, recom-
binant TGF-β was added 60 minutes after 5-aza. All experiments 
were performed with fully confluent cells. In a subset of experiments, 
fibroblasts were incubated with the following cell cycle inhibitors: 
SKPinC1 at 0.5 μM (Tocris, Bio-Techne GmbH), ABT751 at 0.2 μM, 
and AZD5438 at 0.2 μM (both Selleckchem) to exclude confounding 
effects of cell proliferation.
RNAi and overexpression experiments. Dermal fibroblasts were 
transfected with 3 μg of siRNA duplexes against SOCS3, JAK2, 
DNMT1, DNMT3A, SMAD3, or SMAD4 using the 4D-Nucleofector Kit 
for human dermal fibroblasts (Lonza Cologne GmbH), as previously 
described (70, 72). The sequences of the siRNAs are summarized in 
Supplemental Table 1. Fibroblasts transfected with nontargeting siR-
NAs (Eurogentec) served as controls. In order to overexpress SOCS3 in 
dermal fibroblasts, the cDNA of SOCS3 was cloned into pcDNA3.1(+) 
expression vectors (Thermo Fisher Scientific).
The plasmid pGEM-JAK2 encoding the human JAK2 gene was pur-
chased from Sino Biological. In vitro mutagenesis of the GQM-binding 
motif for SOCS3 of JAK2 was performed using the QuikChange Multi 
Site-Directed Mutagenesis Kit (Agilent Technologies) to obtain the 
mutant JAK2-G1071V;M1073A, which cannot be inhibited by SOCS3 
(36). After verification of the correct sequence, the constructs were 
transfected in dermal human fibroblasts using the Lonza 4D-Nucleofec-
tor Kit. Fibroblasts were transfected with 5 μg of plasmids (73). Transfec-
tions with the empty or nonmutated WT vectors were used as controls.
brotic effects of TGF-β, and ameliorates dermal fibrosis. Of note, 
reactivation of SOCS3 expression did not affect collagen release 
of resting fibroblasts from healthy individuals, suggesting that 
this approach may not significantly interfere with homeostat-
ic functions of fibroblasts. More than 10 different clinical trials 
investigating STAT3 inhibitors in various tumors are currently 
ongoing or have been recently completed (e.g., ClinicalTrials.gov 
NCT01563302, NCT01663571, NCT01904123, NCT03195699), 
highlighting that STAT3 is considered as a prime target for phar-
maceutical intervention and that numerous compounds would be 
available for clinical trials in SSc.
Our data also strengthen the scientific rationale for target-
ing DNA methylation in fibrotic diseases. Deletion of Dnmt3a or 
Dnmt1 or pharmacologic inhibition of Dnmts ameliorated fibrosis 
induced by bleomycin or by TBRIact. Of note, treatment with 5-aza 
was not only effective in preventive, but also in therapeutic, set-
tings and not only inhibited further progression, but also induced 
regression of preestablished fibrosis. Inhibition of DNMTs would 
not only limit aberrant STAT3 signaling in SSc, but would also 
exert antifibrotic effects by reactivation of protective genes such 
as FLI1 and KLF5 (29, 30).
However, the simultaneous modulation of several pathways by 
epigenetic modifiers may not only add to the therapeutic effects, 
but may also carry a higher risk of adverse events, as it may also 
interfere with pathways that are not relevant to the pathogenesis 
of SSc. However, these concerns may be limited by recent findings 
that treatment with 5-aza does not cause random DNA demeth-
ylation (65). Instead, treatment with 5-aza predominantly mod-
ulated the expression of a panel of regulatory genes, while it had 
little effects on the methylation status of homeostatic genes. In 
addition to potential effects on fibrotic manifestations, accumulat-
ing evidence suggests that aberrant DNA methylation may also be 
implicated in vascular and inflammatory manifestations of SSc and 
other rheumatic diseases (20, 66, 67). Inhibition of DNA methyla-
tion may thus offer unique potential to improve a broad spectrum 
Figure 8. Mutation of the SOCS3-binding motif of JAK2 abrogates the 
beneficial effects of 5-aza on TGF-β–induced collagen synthesis and 
myofibroblast differentiation. (A) Representative Western blot and quan-
titation of co-IP of JAK2, STAT3, and SOCS3 in normal dermal fibroblasts 
stimulated with TGF-β and incubated with 5-aza. n = 4 fibroblast lines 
from different donors with 3 technical replicates each. (B) Effects of 5-aza 
and of siRNA-mediated knockdown of SOCS3 (left) or DNMT3A (right) on 
TGF-β–induced firefly luciferase activity under the control of a STAT3- 
responsive promoter. n = 6 fibroblast lines from different donors with 3 
technical replicates each. (C) Representative Western blot and quantitation 
of the pSTAT3/STAT3 ratio upon overexpression of WT JAK2 (JAK2-WT) or 
mutated JAK2 with a defective SOCS3-binding site (JAK2-G1071V;M1073A) 
in normal dermal fibroblasts stimulated with TGF-β and incubated with 
5-aza. n = 4 fibroblast lines from different donors with 3 technical replicates 
each. (D) COL1A1 mRNA and collagen protein levels in cell culture media 
upon overexpression of WT JAK2 or mutated JAK2 (n = 5 fibroblast lines 
from different donors with 2 technical replicates each). (E) Representative 
stainings and quantitations of α-SMA (green) and stress fibers (red) upon 
overexpression of WT or mutated JAK2 in normal fibroblasts. n = 3 fibro-
blast lines from different donors with 2 technical replicates each. Original 
magnification, ×400. Scale bars: 100 μm. Data are depicted as the median 
with interquartile range. Each dot represents an individual result. One-way 
ANOVA with Tukey’s range test as post hoc analysis was used for statistical 
analyses. 0.05 > *P ≥ 0.01; 0.01 > **P ≥ 0.001; ***P < 0.001.
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Reporter assay. Fibroblasts were transfected with 1 μg of STAT3-lu-
ciferase reporter construct (QIAGEN) in serum-free medium using 
the Lonza 4D-Nucleofector Kit (73). Transfected cells were incubat-
ed with TGF-β and 5-aza for 16 hours and harvested 36 hours after 
transfection. A noninducible luciferase vector was used as control. 
Luciferase activity was determined using a microplate luminometer 
(Berthold Technologies).
Quantitative real-time PCR. Total RNA was isolated with the Nucle-
oSpin RNA II extraction system (MACHEREY-NAGEL) and reverse 
transcribed into cDNA as described (75, 76). Gene expression was 
quantified by real-time PCR using the Mx3005P Sequence Detection 
System (Agilent Technologies). Specific primer pairs for each gene were 
designed with Primer 3 software. The primer sequences used are given 
in Supplemental Table 3. Measurement of β-actin levels was used to 
normalize for the amounts of loaded cDNA. Samples without enzyme 
in the reverse transcription reaction, without template and dissociation 
curve analysis, served as controls. Differences were calculated with Ct 
and the comparative Ct method for relative quantification.
Western blot. Protein samples were separated by SDS-polyacryl-
amide gel and electrotransferred onto polyvinylidene fluoride (PVDF) 
membranes (Merck Millipore). After blocking, membranes were incu-
bated with mouse anti-SOCS3 (clone SOC-25, catalog 626601, Bio-
Legend), rabbit anti-SOCS3 (polyclonal, catalog ab16030, Abcam), 
rabbit anti-DNMT1 (polyclonal, catalog PLA0011, Sigma-Aldrich), 
rabbit anti-DNMT3A (polyclonal, catalog ab2850, Abcam), mouse 
anti-DNMT3B (clone 52A1018, catalog NB100-56514, Novus Biolog-
icals), rabbit anti-SMAD3 (clone C67H9, catalog 9523, Cell Signaling 
Technology), rabbit anti-SMAD4 (polyclonal, catalog 9515, Cell Sig-
naling Technology), rabbit anti-JAK2 (clone D2E12, catalog 3230, Cell 
Signaling Technology), rabbit anti–phospho-JAK2 (Tyr1007/1008) 
(polyclonal, catalog 3771, Cell Signaling Technology), mouse anti-
Methylation-specific PCR and MeDIP. Genomic DNA was isolated 
from fibroblasts of SSc patients and healthy volunteers using the QIA-
GEN DNeasy Extraction System (QIAGEN) according to the manufac-
turer’s instruction.
For methylation-specific PCR, 2 μg of genomic DNA were pro-
cessed using the EpiTect Bisulfite Kit (QIAGEN). The sequences of 
the primer pairs used for methylation- and unmethylation-specific 
PCR are summarized in Supplemental Table 2. The reaction mixture 
contained 50 ng bisulfite converted DNA in a final volume of 50 μl. 
Each product was loaded onto a 2% agarose gel and visualized under 
ultraviolet illumination. Each band was quantified using ImageJ soft-
ware (NIH, version 1.42).
For MeDIP assay, genomic DNA was fractionated by enzymatic 
digestion with BmrI and EcoP15I (New England Biolabs) and pro-
cessed for immunoprecipitation using the MeDIP Assay Kit from 
Active Motif according to the manufacturer’s protocol. The primer 
sequences used for qPCR are given in Supplemental Table 3.
ChIP. ChIP assays were performed using the ChIP-IT Express Kit 
(Active Motif) as described (74). Anti-SMAD3 Abs (Smad3 [C67H9] 
rabbit mAb, catalog 9523, Cell Signaling Technology) and rabbit IgG 
Abs (catalog sc-2028 [discontinued], Santa Cruz Biotechnologies) 
were used. The primer sequences used for qPCR are given in Supple-
mental Table 3.
DNMT activity assay. DNMT activity was determined using a 
DNMT Activity/Inhibition Assay Kit (Active Motif) according to the 
manufacturer’s protocol. Briefly, nuclear extracts were isolated with 
the nuclear extract kit (Active Motif), and 1.5 μg of nuclear protein 
was incubated with CpG-enriched DNA substrate immobilized on the 
reaction plates for 2.5 hours at 37°C. The absorbance was analyzed at 
450 nm with 655 nm as reference wavelength with a Spectra MAX 190 
microplate spectrophotometer (Molecular Devices).
Figure 9. Graphical summary of the proposed mechanism. (A) Physiological response with temporary upregulation of TGF-β. (B) Mechanism during fibrot-
ic tissue remodeling with persistent activation of TGF-β signaling.
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Biomedical Sciences Research Center [BSRC] “Alexander Fleming,” 
Vari, Greece). Six groups each were analyzed: 3 groups consisted of 
Socs3fl/fl or Dnmt3afl/fl mice; the other 3 groups consisted of Socs3fl/fl 
Col6Cre or Dnmt3afl/fl Col6Cre mice. Two of these 3 groups received 
bleomycin injections for 4 weeks or injections of TBRIact-AAV5, as 
described above. One of the 2 groups was additionally treated with 
5-aza at a dose of 0.5 mg/kg every third day. The third group served as 
a control group and received injections with 0.9% NaCl or LacZ-AAV5.
siRNA-mediated knockdown of Dnmt1 and Dnmt3a in murine skin. 
Female DBA/2 mice 6 weeks of age were purchased from Janvier 
Labs. Complexes of siRNA and atelocollagen (Koken) were prepared 
as described previously (86, 87). The siRNA sequences (Dharmacon, 
Horizon Discovery) are summarized in Supplemental Table 1. Nontar-
geting siRNA duplexes served as controls. Atelocollagen/siRNA com-
plexes were injected intracutaneously once weekly.
Statistics. Results were visualized and analyzed with GraphPad 
Prism, version 8.1.2, and are depicted as the median with interquar-
tile range. Dots represent individual values. For a 2-group comparison, 
Mann-Whitney U test for nonparametric data was used. When more 
than 2 groups of samples were compared, 1-way ANOVA with Tukey’s 
range test as post hoc analysis was used. A P value of less than 0.05 
was considered significant.
Study approval. The study was approved by the local institutional 
review boards (Ethikkommission of the Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg), and all patients and controls included in 
this study signed an approved consent form. The animal experiments 
were approved by the regional government (Regierung von Unterfran-
ken, Würzburg, Germany).
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STAT3 (clone 124H6, catalog 9139, Cell Signaling Technology), or 
rabbit anti–phospho-STAT3 (Tyr705) (clone D3A7, catalog 9145, Cell 
Signaling Technology) overnight at 4°C. Equal loading of proteins was 
confirmed by incubation with mouse anti–β-actin (clone AC-15, cat-
alog A5441, Sigma-Aldrich). Membranes were incubated with horse-
radish peroxidase–conjugated secondary Abs (Agilent Technologies).
Immunohistochemical and immunofluorescence staining. Paraffin-em-
bedded skin sections or cultured fibroblasts were stained with mouse 
anti-P4Hβ (clone RL90, catalog MA3-019, Thermo Fisher Scientific), 
rhodamine-conjugated phalloidin (Thermo Fisher Scientific), mouse 
anti–α-SMA (clone ASM-1/1A4, catalog CBL171-I, Sigma-Aldrich), 
mouse anti-vimentin (clone VI-10, catalog ab20346, Abcam), rabbit 
anti-SOCS3 (polyclonal, catalog ab16030, Abcam), rabbit anti-DN-
MT3A (polyclonal, catalog ab2850, Abcam), goat anti–phospho-JAK2 
(Tyr1007/1008) (polyclonal, catalog sc-21870, Santa Cruz Biotechnolo-
gy), goat anti–phospho-STAT3 (Tyr705) (polyclonal, sc-7993, Santa Cruz 
Biotechnology), and DAPI (CAS 28718-90-3, catalog sc-3598, Santa 
Cruz Biotechnology). Concentration-matched species-specific immu-
noglobulins (Thermo Fisher Scientific) served as control Abs. Stainings 
were analyzed using a Nikon Eclipse 80i microscope.
Co-IP. Fibroblasts were collected in lysis buffer (20 mM Tris-HCl 
pH 8, 137 mM NaCl, 10% glycerol, 1% NP-40, and 2 mM EDTA). Cell 
extracts were incubated with rabbit anti-JAK2 (clone D2E12, catalog 
3230, Cell Signaling Technology) or normal rabbit IgG Abs (Vector 
Laboratories) and 20 μL of protein A/G Agarose (Santa Cruz Bio-
technology). Unbound proteins were removed by washing with PBS. 
Agarose-bound protein complexes were separated via SDS-PAGE fol-
lowed by Western blotting on a PVDF membrane. Ten percent of the 
lysates were used as input.
Collagen measurements. Total soluble collagen in cell culture super-
natants was quantified using the SirCol collagen assay (Biocolor), as 
described (75). The absorbance was determined at 540 nm with a 
Spectra MAX 190 microplate spectrophotometer (Molecular Devices).
Murine models of fibrosis. Fibrosis was induced by subcutaneous 
injections of bleomycin every other day as described (77, 78). In order 
to analyze the efficiency of 5-aza for treatment of established fibrosis, 
the mouse model of preestablished bleomycin-induced dermal fibro-
sis was used in 6-week-old female DBA/2 mice (Janvier Labs) (79). 
One group receiving bleomycin for 6 weeks was additionally treated 
with intraperitoneal injections of 5-aza for the last 3 weeks at a dose of 
0.5 mg/kg every third day.
In addition to the model of bleomycin-induced dermal fibrosis, we 
also used the model of dermal fibrosis induced by local overexpression 
of TBRIact, as previously described (72, 77). Briefly, mice were injected 
with 6.67 × 107 plaque-forming units of TBRIact-AAV5 every other week. 
Control mice were injected with the same amounts of LacZ-encoding 
AAV5. Mice were sacrificed after 8 weeks for further analyses.
Fibrotic changes were analyzed by quantification of the der-
mal thickness, the number of α-SMA–positive myofibroblasts, and 
hydroxyproline content (72, 80–82). Trichrome staining was per-
formed for direct visualization of collagen.
Conditional knockout of Socs3 and Dnmt3a. Mice with conditional 
alleles of Socs3 (Socs3fl/fl) (83) or Dnmt3a (Dnmt3afl/fl) (84) were cross-
bred with Col6-Cre mice (85) to obtain mice with selective knockout 
of Socs3 or Dnmt3a in fibroblasts (Socs3fl/fl Col6Cre or Dnmt3afl/fl Col-
6Cre). Socs3fl/fl mice and Dnmt3afl/fl mice were provided in-house, and 
Col6Cre mice were obtained from G. Kollias (Institute of Immunology, 
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